EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data

EyePoint, Inc.

First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.
Non-inferiority design vs aflibercept; primary endpoint is BCVA change from baseline at weeks 52 and 56.
New preclinical data shows vorolanib inhibits IL-6 mediated inflammation via JAK receptors, adding to VEGF blockade.
Company had positive end-of-Phase 2 meeting with FDA; DURAVYU also in Phase 3 for wet AMD.
Estimated cash and investments as of Sept 30, 2025 included in investor presentation (not specified).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.